They've already shown the relationship between degree of slowed gastric emptying vs weight loss from these is weak. It looks like maybe they can explain it just from baseline glp-1. Wish they had done a continuous regression of that vs weight loss, regardless of cluster. By rank order it works:
@ResearchPulse1 No, that can't explain this. It's just not how glp-1 dose-response works, they all fall on a single curve til plateau and you don't get such an outsized jump from proportional increase (amylins and DACRAs are a little different)
$NVO $HIMS symmetry here. A common heuristic is a >=candle in the opposite direction breaks a trend. NVO needs a 16-20% + gap up day (HIMS already had back in feb). Both have declining 200 dma, HIMS below, NVO testing. I'm long HIMS puts, looking to buy back longer-dated NVO puts
I think by the end of the decade $NVO will run a head-to-head of ubt 251 vs tzp and they'll of course beat it on weight loss. Of course the side effects will be horrible for them but they will put off publishing it for a full year and they will leave all AE data out of the pr. So then they can at least brag about it for a little bit. They'd probably have to hurry up and start it soon so they can use the excuse of not running against reta that it wasn't available yet.
And every serious analyst will scoff and see it as a joke. But all sad bag holders will post about it all over Twitter 😂
You heard it here first.
@Ashwinreads Do you know which trial they're looking at here for phase 3? The ae rates dont match surpass 1 or surmount-2. Wish they would have cited the specific paper instead of just the journal.
@bioinvestor24 I think -3.6% for PWS could be quite meaningful? But there is no control arm and they don't even tell us the participants' weight trajectory prior to starting the medication. Or how their home environment is set up, could it reflect a change in the caretakers' actions?
@Idomeneus_OG Well given Novo's recent track record at picking drugs, it would be a surprise if it's anything better than "reta, but you need a smaller dose"